ketamine has been researched along with Psychoses, Drug in 81 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketamine mimicked the performance of schizophrenia patients on the intentional binding task, significantly increasing binding relative to placebo." | 9.15 | Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia. ( Absalom, AR; Adapa, R; Arana, FS; Corlett, PR; de Wit, S; Everitt, JC; Fletcher, PC; Gardner, JM; Haggard, P; Moore, JW; Morgan, HL; Pigott, JS; Turner, DC, 2011) |
| " The ketamine challenge study in schizophrenia subjects is at the vortex of the current debate." | 9.09 | The schizophrenia ketamine challenge study debate. ( Carpenter, WT, 1999) |
| "The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia." | 8.98 | Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. ( Curic, S; Haaf, M; Leicht, G; Mulert, C, 2018) |
| "Psychotomimetics like the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine and the 5-hydroxytryptamine2A receptor (5-HT(2A)R) agonist psilocybin induce psychotic symptoms in healthy volunteers that resemble those of schizophrenia." | 5.16 | Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. ( Bachmann, R; Csomor, PA; Kometer, M; Schmidt, A; Seifritz, E; Stephan, KE; Vollenweider, FX, 2012) |
| "Ketamine mimicked the performance of schizophrenia patients on the intentional binding task, significantly increasing binding relative to placebo." | 5.15 | Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia. ( Absalom, AR; Adapa, R; Arana, FS; Corlett, PR; de Wit, S; Everitt, JC; Fletcher, PC; Gardner, JM; Haggard, P; Moore, JW; Morgan, HL; Pigott, JS; Turner, DC, 2011) |
| "Ketamine induces effects resembling both positive and negative psychotic symptoms of schizophrenia." | 5.13 | Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. ( Arstad, E; Bressan, RA; Ell, PJ; Erlandsson, K; Krystal, JH; Pilowsky, LS; Squassante, L; Stone, JM; Teneggi, V, 2008) |
| " The ketamine challenge study in schizophrenia subjects is at the vortex of the current debate." | 5.09 | The schizophrenia ketamine challenge study debate. ( Carpenter, WT, 1999) |
| "Ketamine (1) produced behaviors similar to the positive and negative symptoms of schizophrenia; (2) elicited alterations in perception; (3) impaired performance on tests of vigilance, verbal fluency, and the Wisconsin Card Sorting Test; (4) evoked symptoms similar to dissociative states; and (5) preferentially disrupted delayed word recall, sparing immediate recall and postdistraction recall." | 5.07 | Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. ( Bowers, MB; Bremner, JD; Charney, DS; Delaney, R; Freeman, GK; Heninger, GR; Karper, LP; Krystal, JH; Seibyl, JP, 1994) |
| "The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia." | 4.98 | Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. ( Curic, S; Haaf, M; Leicht, G; Mulert, C, 2018) |
| "Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors." | 4.88 | Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. ( Heresco-Levy, U; Javitt, DC; Umbricht, D; Zukin, SR, 2012) |
| "The research of the glutamatergic system in schizophrenia has advanced with the use of non-competitive antagonists of glutamate NMDA receptors (phencyclidine, ketamine, and dizocilpine), which change both human and animal behaviour and induce schizophrenia-like manifestations." | 4.84 | Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. ( Bubeníková-Valesová, V; Horácek, J; Höschl, C; Vrajová, M, 2008) |
| "Ketamine produces effects in healthy humans that resemble the positive, negative and cognitive symptoms of schizophrenia." | 3.81 | Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe. ( De Simoni, S; Dietrich, C; Kotoula, V; Krystal, JH; Mehta, MA; Stone, J, 2015) |
| "The aim of this study is to investigate the effects of pregabalin on the behavior of rats under the influence of ketamine, an NMDA receptor antagonist that mimics the symptoms of schizophrenia." | 3.78 | Effects of pregabalin on behavioral alterations induced by ketamine in rats. ( Baker, GB; Canever, L; Crippa, JA; Dursun, SM; Hallak, JE; Luca, RD; Nunes, EA; Oliveira, Ld; Peregrino, A; Quevedo, J; Zugno, A, 2012) |
| "Ketamine induced a range of perceptual distortions, but not hallucinations." | 3.73 | Psychological effects of ketamine in healthy volunteers. Phenomenological study. ( Absalom, AR; Bullmore, ET; Corlett, PR; Fletcher, PC; Honey, GD; Lee, M; McKenna, PJ; Murray, GK; Pomarol-Clotet, E, 2006) |
| "Ketamine was found to constitute a robust model for induction of psychomimetic symptoms and the optimal concentration range for a drug interaction study would be between 100 and 200 ng/mL." | 2.80 | Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers. ( Dahan, A; Freijer, J; Klaassen, E; Kleinloog, D; Mooren, R; Stevens, J; Uit den Boogaard, A; van Gerven, J, 2015) |
| "Ketamine was associated with psychotic and dissociative symptoms." | 2.76 | Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation. ( Abel, KM; Allin, MP; Fu, CH; Matsumoto, K; McGuire, PK; Stone, JM; van Haren, N, 2011) |
| "Lamotrigine pretreatment prevented many of the BOLD signal changes and the symptoms." | 2.73 | Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. ( Deakin, JF; Dursun, SM; Hallak, JE; Lees, J; McKie, S; Williams, SR, 2008) |
| " The magnitude of ketamine-induced changes in positive symptoms was similar, although the psychosis baseline differed, and the dose-response profiles over time were superimposable across the two populations." | 2.70 | Effects of ketamine in normal and schizophrenic volunteers. ( Lahti, AC; Parwani, A; Tamara Michaelidis, BA; Tamminga, CA; Weiler, MA, 2001) |
| "The frequency of psychosis emergence or confusion (54%) in Group A during the first 48 hours after surgery was significantly higher than the 30% figure in Group B." | 2.70 | Anesthesia with ketamine, propofol, and fentanyl decreases the frequency of postoperative psychosis emergence and confusion in schizophrenic patients. ( Katagai, H; Kudoh, A; Takazawa, T, 2002) |
| "(R)-ketamine did not produce psychotic symptoms, but a state of relaxation." | 2.68 | Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). ( Angst, J; Hell, D; Leenders, KL; Oye, I; Vollenweider, FX, 1997) |
| " On several counts, the combination of ketamine and flunitrazepam was proved to reduce the adverse reactions seen with ketamine alone." | 2.64 | Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial. ( Freuchen, I; Kühl, JB; Mikkelsen, BO; Ostergaard, J, 1976) |
| "Ketamine vs placebo was associated with enhanced neural responses in the right middle and inferior temporal gyri." | 1.48 | S-Ketamine-Induced NMDA Receptor Blockade during Natural Speech Production and Its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study. ( Cabanis, M; Kircher, T; Kirner-Veselinovic, A; Nagels, A; Oppel, A; Schales, C, 2018) |
| "Ketamine is an anaesthetic and analgesic drug synthesized in the 1960s from phencyclidine." | 1.40 | Paliperidone for the treatment of ketamine-induced psychosis: a case report. ( Carrozzino, R; Fucile, C; Martelli, A; Mattioli, F; Muscella, A; Orengo, S; Zuccoli, ML, 2014) |
| "Ketamine is often used to manage neuropathic pain in patients with cancer." | 1.39 | Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer? ( Matsuda, Y; Ohno, Y; Okamoto, Y; Tanimukai, H; Tsugane, M; Tsuneto, S; Uejima, E, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (9.88) | 18.7374 |
| 1990's | 9 (11.11) | 18.2507 |
| 2000's | 30 (37.04) | 29.6817 |
| 2010's | 32 (39.51) | 24.3611 |
| 2020's | 2 (2.47) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ST | 1 |
| Hsieh, CP | 1 |
| Lee, MY | 1 |
| Chen, LC | 1 |
| Huang, CM | 1 |
| Chen, HH | 1 |
| Chan, MH | 1 |
| McIntyre, RS | 1 |
| Rosenblat, JD | 1 |
| Nemeroff, CB | 1 |
| Sanacora, G | 1 |
| Murrough, JW | 1 |
| Berk, M | 1 |
| Brietzke, E | 1 |
| Dodd, S | 1 |
| Gorwood, P | 1 |
| Ho, R | 1 |
| Iosifescu, DV | 1 |
| Lopez Jaramillo, C | 1 |
| Kasper, S | 1 |
| Kratiuk, K | 1 |
| Lee, JG | 1 |
| Lee, Y | 1 |
| Lui, LMW | 1 |
| Mansur, RB | 1 |
| Papakostas, GI | 1 |
| Subramaniapillai, M | 1 |
| Thase, M | 1 |
| Vieta, E | 1 |
| Young, AH | 1 |
| Zarate, CA | 1 |
| Stahl, S | 1 |
| Ma, J | 2 |
| Stan Leung, L | 1 |
| Leung, LS | 1 |
| Nagels, A | 1 |
| Cabanis, M | 1 |
| Oppel, A | 1 |
| Kirner-Veselinovic, A | 1 |
| Schales, C | 1 |
| Kircher, T | 1 |
| Haaf, M | 1 |
| Leicht, G | 1 |
| Curic, S | 1 |
| Mulert, C | 1 |
| Tian, LL | 1 |
| Newman, WJ | 1 |
| Dong, H | 1 |
| Yang, C | 1 |
| Shen, Y | 1 |
| Liu, L | 1 |
| Liu, M | 1 |
| Hao, W | 1 |
| Nunes, EA | 1 |
| Canever, L | 1 |
| Oliveira, Ld | 1 |
| Luca, RD | 1 |
| Quevedo, J | 1 |
| Zugno, A | 1 |
| Peregrino, A | 1 |
| Crippa, JA | 1 |
| Dursun, SM | 3 |
| Baker, GB | 1 |
| Hallak, JE | 3 |
| Carhart-Harris, RL | 1 |
| Brugger, S | 1 |
| Nutt, DJ | 1 |
| Stone, JM | 4 |
| Zhou, Z | 1 |
| Zhang, G | 1 |
| Li, X | 1 |
| Liu, X | 1 |
| Wang, N | 1 |
| Qiu, L | 1 |
| Liu, W | 1 |
| Zuo, Z | 1 |
| Yang, J | 1 |
| Dandash, O | 1 |
| Harrison, BJ | 1 |
| Adapa, R | 3 |
| Gaillard, R | 2 |
| Giorlando, F | 1 |
| Wood, SJ | 1 |
| Fletcher, PC | 7 |
| Fornito, A | 2 |
| Xu, K | 1 |
| Lipsky, RH | 1 |
| Zuccoli, ML | 1 |
| Muscella, A | 1 |
| Fucile, C | 1 |
| Carrozzino, R | 1 |
| Mattioli, F | 1 |
| Martelli, A | 1 |
| Orengo, S | 1 |
| MBSc, EN | 1 |
| Joshua, N | 1 |
| Morgan, C | 1 |
| Rossell, SL | 1 |
| Kleinloog, D | 1 |
| Uit den Boogaard, A | 1 |
| Dahan, A | 1 |
| Mooren, R | 1 |
| Klaassen, E | 1 |
| Stevens, J | 1 |
| Freijer, J | 1 |
| van Gerven, J | 1 |
| Vinckier, F | 1 |
| Palminteri, S | 1 |
| Rigoux, L | 1 |
| Salvador, A | 1 |
| Krebs, MO | 1 |
| Pessiglione, M | 1 |
| Stone, J | 1 |
| Kotoula, V | 1 |
| Dietrich, C | 1 |
| De Simoni, S | 1 |
| Krystal, JH | 6 |
| Mehta, MA | 2 |
| Francois, J | 1 |
| Grimm, O | 1 |
| Schwarz, AJ | 1 |
| Schweiger, J | 1 |
| Haller, L | 1 |
| Risterucci, C | 1 |
| Böhringer, A | 1 |
| Zang, Z | 1 |
| Tost, H | 1 |
| Gilmour, G | 1 |
| Meyer-Lindenberg, A | 1 |
| Corlett, PR | 5 |
| Honey, GD | 4 |
| Steffens, M | 1 |
| Becker, B | 1 |
| Neumann, C | 1 |
| Kasparbauer, AM | 1 |
| Meyhöfer, I | 1 |
| Weber, B | 1 |
| Hurlemann, R | 1 |
| Ettinger, U | 1 |
| Khlestova, E | 1 |
| Johnson, JW | 1 |
| Lisman, J | 1 |
| Zorumski, CF | 1 |
| Izumi, Y | 1 |
| Mennerick, S | 1 |
| Absalom, AR | 4 |
| Lee, M | 3 |
| Pomarol-Clotet, E | 3 |
| Murray, GK | 3 |
| McKenna, PJ | 3 |
| Bullmore, ET | 3 |
| Menon, DK | 1 |
| Daumann, J | 5 |
| Heekeren, K | 5 |
| Neukirch, A | 5 |
| Thiel, CM | 2 |
| Möller-Hartmann, W | 1 |
| Gouzoulis-Mayfrank, E | 5 |
| Grande Fullana, I | 1 |
| To Figueras, J | 1 |
| Goti Elejalde, J | 1 |
| Smalla, KH | 1 |
| Sahin, J | 1 |
| Putzke, J | 1 |
| Tischmeyer, W | 1 |
| Gundelfinger, ED | 1 |
| Kreutz, MR | 1 |
| Wagner, D | 1 |
| Sorce, S | 1 |
| Schiavone, S | 1 |
| Tucci, P | 1 |
| Colaianna, M | 1 |
| Jaquet, V | 1 |
| Cuomo, V | 1 |
| Dubois-Dauphin, M | 1 |
| Trabace, L | 1 |
| Krause, KH | 1 |
| Abel, KM | 3 |
| Allin, MP | 3 |
| van Haren, N | 1 |
| Matsumoto, K | 1 |
| McGuire, PK | 2 |
| Fu, CH | 2 |
| Moore, JW | 1 |
| Turner, DC | 1 |
| Arana, FS | 1 |
| Morgan, HL | 1 |
| de Wit, S | 1 |
| Everitt, JC | 1 |
| Gardner, JM | 1 |
| Pigott, JS | 1 |
| Haggard, P | 1 |
| Schmidt, A | 1 |
| Bachmann, R | 1 |
| Kometer, M | 1 |
| Csomor, PA | 1 |
| Stephan, KE | 1 |
| Seifritz, E | 1 |
| Vollenweider, FX | 5 |
| D'Souza, DC | 2 |
| Singh, N | 1 |
| Elander, J | 1 |
| Carbuto, M | 1 |
| Pittman, B | 1 |
| Udo de Haes, J | 1 |
| Sjogren, M | 1 |
| Peeters, P | 1 |
| Ranganathan, M | 1 |
| Schipper, J | 1 |
| Chatterjee, M | 1 |
| Verma, R | 1 |
| Ganguly, S | 1 |
| Palit, G | 1 |
| Ebert, A | 1 |
| Haussleiter, IS | 1 |
| Juckel, G | 1 |
| Brüne, M | 1 |
| Roser, P | 1 |
| Okamoto, Y | 1 |
| Tsuneto, S | 1 |
| Tanimukai, H | 1 |
| Matsuda, Y | 1 |
| Ohno, Y | 1 |
| Tsugane, M | 1 |
| Uejima, E | 1 |
| Moghaddam, B | 1 |
| Javitt, DC | 1 |
| Zukin, SR | 1 |
| Heresco-Levy, U | 1 |
| Umbricht, D | 2 |
| Hemsley, DR | 1 |
| Geyer, MA | 2 |
| Lim, DK | 1 |
| Lees, J | 2 |
| Deakin, JF | 2 |
| Aalto, S | 1 |
| Ihalainen, J | 1 |
| Hirvonen, J | 1 |
| Kajander, J | 1 |
| Scheinin, H | 1 |
| Tanila, H | 1 |
| Någren, K | 1 |
| Vilkman, H | 1 |
| Gustafsson, LL | 1 |
| Syvälahti, E | 1 |
| Hietala, J | 1 |
| Stoll, M | 2 |
| Stock, C | 2 |
| Obradovic, M | 2 |
| Kovar, KA | 2 |
| Perry, EB | 1 |
| Gueorguieva, R | 1 |
| Belger, A | 1 |
| Madonick, SH | 1 |
| Abi-Dargham, A | 1 |
| Cooper, TB | 1 |
| Macdougall, L | 1 |
| Abi-Saab, W | 1 |
| Gasston, D | 1 |
| Costafreda, SG | 1 |
| Suckling, J | 1 |
| Williams, SC | 1 |
| Aitken, MR | 1 |
| Dickinson, A | 1 |
| Shanks, DR | 1 |
| Robbins, TW | 1 |
| Pilowsky, LS | 2 |
| Sharp, FR | 1 |
| Hendren, RL | 1 |
| Boeijinga, PH | 1 |
| Soufflet, L | 1 |
| Santoro, F | 1 |
| Luthringer, R | 1 |
| Covington, MA | 1 |
| Riedel, WJ | 1 |
| Brown, C | 1 |
| He, C | 1 |
| Morris, E | 1 |
| Weinstein, S | 1 |
| Semple, J | 1 |
| Brown, J | 1 |
| Tsai, GE | 1 |
| Erlandsson, K | 1 |
| Arstad, E | 1 |
| Squassante, L | 1 |
| Teneggi, V | 1 |
| Bressan, RA | 1 |
| Ell, PJ | 1 |
| McKie, S | 1 |
| Williams, SR | 1 |
| Mason, OJ | 1 |
| Morgan, CJ | 1 |
| Stefanovic, A | 1 |
| Curran, HV | 1 |
| Bubeníková-Valesová, V | 1 |
| Horácek, J | 1 |
| Vrajová, M | 1 |
| Höschl, C | 1 |
| Kawohl, W | 1 |
| Norra, C | 1 |
| Waberski, TD | 1 |
| Baer, G | 1 |
| Parkas, P | 1 |
| Feng, N | 1 |
| Minder, EI | 1 |
| Rentsch, K | 1 |
| Grampp, T | 1 |
| Vonderschmitt, DJ | 1 |
| Karper, LP | 1 |
| Seibyl, JP | 1 |
| Freeman, GK | 1 |
| Delaney, R | 1 |
| Bremner, JD | 1 |
| Heninger, GR | 1 |
| Bowers, MB | 1 |
| Charney, DS | 1 |
| Lahti, AC | 2 |
| Koffel, B | 1 |
| LaPorte, D | 1 |
| Tamminga, CA | 2 |
| Leenders, KL | 2 |
| Scharfetter, C | 1 |
| Antonini, A | 1 |
| Maguire, P | 1 |
| Missimer, J | 1 |
| Angst, J | 2 |
| Oye, I | 1 |
| Hell, D | 1 |
| Breier, A | 2 |
| Malhotra, AK | 2 |
| Pinals, DA | 1 |
| Weisenfeld, NI | 1 |
| Pickar, D | 2 |
| Goldman, D | 1 |
| Picken, L | 1 |
| Newcomer, JW | 1 |
| Farber, NB | 1 |
| Jevtovic-Todorovic, V | 1 |
| Selke, G | 1 |
| Melson, AK | 1 |
| Hershey, T | 1 |
| Craft, S | 1 |
| Olney, JW | 1 |
| Carpenter, WT | 1 |
| Grunze, H | 1 |
| Gallinat, J | 1 |
| Haag, C | 1 |
| Hegerl, U | 1 |
| Green, SM | 1 |
| Li, J | 1 |
| Giannini, AJ | 1 |
| Underwood, NA | 1 |
| Condon, M | 1 |
| Weiler, MA | 1 |
| Tamara Michaelidis, BA | 1 |
| Parwani, A | 1 |
| Koller, R | 1 |
| Schmid, L | 1 |
| Kudoh, A | 1 |
| Katagai, H | 1 |
| Takazawa, T | 1 |
| Freuchen, I | 1 |
| Ostergaard, J | 1 |
| Kühl, JB | 1 |
| Mikkelsen, BO | 1 |
| Siegel, RK | 1 |
| Dipalma, JR | 1 |
| Peltz, B | 1 |
| Sinclair, DM | 1 |
| Davidson, J | 1 |
| Brewer, C | 1 |
| Johnson, BD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Intravenous Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth in Women With Prenatal Depression: 2-year Follow-up of a Randomized Controlled Trial[NCT05698394] | Phase 4 | 364 participants (Actual) | Interventional | 2020-06-19 | Active, not recruiting | ||
| Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State[NCT06133309] | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| A Double-Blind, 2-Way Crossover Study to Investigate the Effects of JNJ-40411813 on Ketamine-Induced Alterations in Neuropsychiatric Performance[NCT01101659] | Phase 1 | 40 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885] | 16 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Intravenous Ketamine Effects on Functional Neuroanatomy[NCT04205890] | Phase 1 | 0 participants (Actual) | Interventional | 2020-05-02 | Withdrawn (stopped due to Sponsor is no longer interested in funding the study) | ||
| Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial[NCT02533232] | Phase 1 | 60 participants (Anticipated) | Interventional | 2022-08-30 | Recruiting | ||
| The Effect of a Single Dose of Lamotrigine on Brain Function in Healthy Volunteers[NCT04396938] | 36 participants (Actual) | Interventional | 2017-05-10 | Completed | |||
| Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder[NCT03748446] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2019-12-05 | Recruiting | ||
| Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders[NCT02579928] | Phase 4 | 17 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen[NCT00626340] | Phase 4 | 18 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia[NCT03323437] | Phase 4 | 47 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2019-07-17 | Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.) | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Predictive Coding Abnormalities in Psychosis: EEG and fMRI[NCT03068806] | 202 participants (Actual) | Observational | 2014-12-01 | Completed | |||
| Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion[NCT03751423] | Phase 3 | 123 participants (Anticipated) | Interventional | 2019-06-10 | Suspended (stopped due to Study on-hold due to COVID-19 pandemic restrictions. Will resume when possible.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.17 |
| Placebo | -0.094 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.1 |
| Placebo | 0.052 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.134 |
| Placebo | -0.086 |
"Depressive symptoms (measured by Montgomery-Asberg Depression Rating Scale, revised (MADRS) score) on 1 day after infusion, for the cohort of subjects enrolled in the MDD arm of this trial.~Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal /symptom absent. 7 to 19 - mild depression. 20 to 34 - moderate depression. >34 - severe depression." (NCT02579928)
Timeframe: 1 day after the infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 15.44 |
| Midazolam | 24.13 |
"This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable to contact for additional information.~We only know that 18 participants completed, but as far as we know data was never analyzed for these 18 participants." (NCT00626340)
Timeframe: Healthy controls will undergo scans pre and post 3 weeks of estrogen treatment. Women with depression will undergo scans pre and post 6 weeks of treatment with estrogen alone, estrogen and fluoxetine, or fluoxetine alone
| Intervention | () |
|---|---|
| All Participants | 0 |
Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine | 42 |
| Midazolam | 62 |
Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 0 |
| Midazolam | 0 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
8 reviews available for ketamine and Psychoses, Drug
| Article | Year |
|---|---|
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Tre | 2021 |
Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.
Topics: Animals; Biomarkers; Disease Models, Animal; Electroencephalography; Excitatory Amino Acid Antagonis | 2018 |
Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans.
Topics: Excitatory Amino Acid Antagonists; Gene Expression Regulation; Genetic Predisposition to Disease; Hu | 2015 |
Prediction error, ketamine and psychosis: An updated model.
Topics: Animals; Association Learning; Brain; Delusions; Hallucinations; Humans; Ketamine; Psychoses, Substa | 2016 |
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cerebral Corte | 2012 |
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Brain Mapping; Cerebral Cortex; Cognition Disorders; Contingen | 2012 |
Psychosis: atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?
Topics: Adolescent; Animals; Antipsychotic Agents; Dizocilpine Maleate; Epilepsy; Excitatory Amino Acid Anta | 2007 |
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Topics: Adaptation, Physiological; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Human | 2008 |
35 trials available for ketamine and Psychoses, Drug
| Article | Year |
|---|---|
Selective augmentation of striatal functional connectivity following NMDA receptor antagonism: implications for psychosis.
Topics: Adult; Corpus Striatum; Double-Blind Method; Female; Frontal Lobe; Functional Neuroimaging; Humans; | 2015 |
The effect of ketamine on configural facial processing.
Topics: Adolescent; Adult; Double-Blind Method; Excitatory Amino Acid Antagonists; Face; Female; Humans; Ket | 2015 |
Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.
Topics: Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Excita | 2015 |
Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study.
Topics: Acoustic Stimulation; Animals; Anticipation, Psychological; Brain Mapping; Conditioning, Classical; | 2016 |
Effects of ketamine on brain function during smooth pursuit eye movements.
Topics: Adult; Attention; Brain; Brain Mapping; Cerebrovascular Circulation; Double-Blind Method; Excitatory | 2016 |
Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.
Topics: Adult; Attention; Cross-Over Studies; Cues; Double-Blind Method; Female; Humans; Inhibition, Psychol | 2008 |
Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis.
Topics: Adult; Attention; Auditory Perception; Brain; Cross-Over Studies; Cues; Double-Blind Method; Female; | 2010 |
Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation.
Topics: Adult; Double-Blind Method; Feedback, Psychological; Humans; Ketamine; Magnetic Resonance Imaging; M | 2011 |
Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Female; Healthy Voluntee | 2011 |
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
Topics: Adult; Cognition Disorders; Double-Blind Method; Electroencephalography; Excitatory Amino Acid Antag | 2012 |
Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.
Topics: Adult; Anesthetics, Dissociative; Cross-Over Studies; Glycine Plasma Membrane Transport Proteins; Hu | 2012 |
Low dose ketamine increases prepulse inhibition in healthy men.
Topics: Acoustic Stimulation; Cognition; Cross-Over Studies; Disease Models, Animal; Double-Blind Method; El | 2003 |
Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Topics: Adult; Attention; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 2006 |
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Topics: Amphetamine; Cognition; Dopamine; Double-Blind Method; Drug Interactions; Glutamine; Humans; Ketamin | 2005 |
Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: a functional magnetic resonance imaging study.
Topics: Corpus Striatum; Double-Blind Method; Excitatory Amino Acid Antagonists; Humans; Ketamine; Magnetic | 2005 |
Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis.
Topics: Adult; Association Learning; Brief Psychiatric Rating Scale; Cognition Disorders; Delusions; Disease | 2006 |
Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
Topics: Adult; Attention; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Hallucinogens; Hum | 2007 |
Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man.
Topics: Acoustic Stimulation; Adult; Auditory Perception; Double-Blind Method; Electroencephalography; Excit | 2007 |
Does ketamine mimic aspects of schizophrenic speech?
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Excitatory Amino A | 2007 |
Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.
Topics: Adult; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Guanidines; Humans; Infusio | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Topics: Adult; Anticonvulsants; Awareness; Brain; Brief Psychiatric Rating Scale; Cross-Over Studies; Dissoc | 2008 |
Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Topics: Adult; Attention; Auditory Perception; Brain Mapping; Cerebral Cortex; Contingent Negative Variation | 2008 |
Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Gas Chromatography-Mass Spectrometry; Humans; K | 1995 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glutamic Acid; Haloperidol; Hu | 1995 |
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).
Topics: Adult; Brain Chemistry; Deoxyglucose; Excitatory Amino Acid Antagonists; Female; Fluorine Radioisoto | 1997 |
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).
Topics: Adult; Brain Chemistry; Cerebral Cortex; Female; Functional Laterality; Glucose; Humans; Ketamine; K | 1997 |
The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report.
Topics: Adult; Affect; Apolipoprotein E4; Apolipoproteins E; Brief Psychiatric Rating Scale; Double-Blind Me | 1998 |
Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.
Topics: Adult; Animals; Cognition; Depression, Chemical; Dose-Response Relationship, Drug; Double-Blind Meth | 1999 |
The schizophrenia ketamine challenge study debate.
Topics: Anesthetics, Dissociative; Anxiety; Bioethics; Brief Psychiatric Rating Scale; Consumer Product Safe | 1999 |
Acute ketamine intoxication treated by haloperidol: a preliminary study.
Topics: Adult; Anesthetics, Dissociative; Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Ke | 2000 |
Effects of ketamine in normal and schizophrenic volunteers.
Topics: Adult; Behavior; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Female; Humans | 2001 |
Anesthesia with ketamine, propofol, and fentanyl decreases the frequency of postoperative psychosis emergence and confusion in schizophrenic patients.
Topics: Adult; Aged; Anesthesia, General; Anesthesia, Intravenous; Anesthetics, Dissociative; Anesthetics, I | 2002 |
Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial.
Topics: Abortion, Induced; Adolescent; Adult; Anesthesia, Intravenous; Anti-Anxiety Agents; Blood Pressure; | 1976 |
Induction agents for Caesarean section. A comparison of thiopentone and ketamine.
Topics: Anesthesia, General; Anesthesia, Obstetrical; Apgar Score; Cesarean Section; Cognition; Dreams; Fema | 1973 |
38 other studies available for ketamine and Psychoses, Drug
| Article | Year |
|---|---|
Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Betaine; Cognition; Disease Models, Animal; Disks L | 2021 |
Effects of GABA-B receptor positive modulator on ketamine-induced psychosis-relevant behaviors and hippocampal electrical activity in freely moving rats.
Topics: Anesthetics, Dissociative; Animals; Evoked Potentials, Auditory; GABA-B Receptor Agonists; Hippocamp | 2017 |
Involvement of posterior cingulate cortex in ketamine-induced psychosis relevant behaviors in rats.
Topics: Acoustic Stimulation; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Evoked Potentials | 2018 |
S-Ketamine-Induced NMDA Receptor Blockade during Natural Speech Production and Its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study.
Topics: Adult; Brain; Brain Mapping; Cerebrovascular Circulation; Cross-Over Studies; Double-Blind Method; E | 2018 |
Psychiatric Considerations Regarding Prehospital Administration of Ketamine for Agitation.
Topics: Conscious Sedation; Emergency Medical Services; Humans; Hypnotics and Sedatives; Ketamine; Male; Psy | 2019 |
Effects of ketamine use on psychotic disorders and symptoms in male, methamphetamine-dependent subjects.
Topics: Adult; Amphetamine-Related Disorders; Central Nervous System Stimulants; Humans; Ketamine; Male; Met | 2019 |
Effects of pregabalin on behavioral alterations induced by ketamine in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.
Topics: Amphetamine; Cannabis; Drug Users; Ethanol; Female; Humans; Ketamine; Male; Mental Disorders; Pilot | 2013 |
Loss of phenotype of parvalbumin interneurons in rat prefrontal cortex is involved in antidepressant- and propsychotic-like behaviors following acute and repeated ketamine administration.
Topics: Animals; Antidepressive Agents; Drug Administration Schedule; Interneurons; Ketamine; Male; Parvalbu | 2015 |
Paliperidone for the treatment of ketamine-induced psychosis: a case report.
Topics: Adult; Anesthetics, Dissociative; Antipsychotic Agents; Hospitalization; Humans; Isoxazoles; Ketamin | 2014 |
Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade.
Topics: Adult; Bayes Theorem; Conditioning, Classical; Double-Blind Method; Female; Humans; Ketamine; Learni | 2016 |
Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe.
Topics: Adolescent; Adult; Anesthetics, Dissociative; Delusions; Humans; Ketamine; Magnetic Resonance Imagin | 2015 |
The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models.
Topics: Animals; Brain; Evidence-Based Medicine; Hallucinogens; Humans; Ketamine; Psychoses, Substance-Induc | 2016 |
Ketamine: NMDA Receptors and Beyond.
Topics: Animals; Brain; Evidence-Based Medicine; Hallucinogens; Humans; Ketamine; Psychoses, Substance-Induc | 2016 |
Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo.
Topics: Adult; Brain; Female; Humans; Individuality; Ketamine; Learning; Magnetic Resonance Imaging; Male; P | 2008 |
[Ketamine-induced pychosis].
Topics: Adult; Female; Humans; Ketamine; Psychoses, Substance-Induced | 2008 |
Altered postsynaptic-density-levels of caldendrin in the para-chloroamphetamine-induced serotonin syndrome but not in the rat ketamine model of psychosis.
Topics: Animals; Blotting, Western; Calcium-Binding Proteins; Excitatory Amino Acid Antagonists; Ketamine; M | 2009 |
The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Ketamine; Membrane Glycoproteins; Mice; Mice, Inbred | 2010 |
Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice.
Topics: Acetylcholine; Acetylcholinesterase; Amino Acids; Animals; Behavior, Animal; Biogenic Monoamines; Bi | 2012 |
Impaired facial emotion recognition in a ketamine model of psychosis.
Topics: Adult; Attention; Emotions; Excitatory Amino Acid Antagonists; Facial Expression; Humans; Ketamine; | 2012 |
Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer?
Topics: Adolescent; Adult; Aged; Analgesics; Child; Female; Humans; Infusions, Intravenous; Ketamine; Male; | 2013 |
Ketamine associated psychedelic effects and dependence.
Topics: Adult; Anesthetics, Dissociative; Humans; Ketamine; Male; Psychoses, Substance-Induced | 2003 |
Gender differences and the effects of ketamine in healthy volunteers.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Ketamine; Male; Psychoses | 2004 |
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.
Topics: Adult; Animals; Carbon Radioisotopes; Cerebral Cortex; Dopamine; Excitatory Amino Acid Antagonists; | 2005 |
Psychological effects of ketamine in healthy volunteers. Phenomenological study.
Topics: Adult; Brief Psychiatric Rating Scale; Central Nervous System; Cognition Disorders; Delusions; Excit | 2006 |
Psychopathological consequences of ketamine.
Topics: Adult; Brief Psychiatric Rating Scale; Delusions; Excitatory Amino Acid Antagonists; Female; Halluci | 2006 |
Searching for rational anti N-methyl-D-aspartate treatment for depression.
Topics: Cognition Disorders; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine; N-Met | 2007 |
The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis.
Topics: Adolescent; Adult; Affective Symptoms; Anesthetics, Dissociative; Bipolar Disorder; Cognition Disord | 2008 |
[Ketamine-induced psychopathological changes in normal volunteers during conditions used for experimental psychoses (author's transl)].
Topics: Adult; Anesthesia; Female; Hallucinogens; Humans; Ketamine; Male; Psychoses, Substance-Induced; Thio | 1981 |
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.
Topics: Adult; Deoxyglucose; Dose-Response Relationship, Drug; Female; Fluorine Radioisotopes; Fluorodeoxygl | 1997 |
Psychopathological and auditory evoked potential correlates of ketamine psychosis--a single case report.
Topics: Anesthetics, Dissociative; Brain Mapping; Cerebral Cortex; Dominance, Cerebral; Electroencephalograp | 2000 |
Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions.
Topics: Adolescent; Adult; Aged; Anesthetics, Dissociative; Emergency Service, Hospital; Humans; Ketamine; M | 2000 |
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
Topics: Administration, Oral; Adult; Cerebral Cortex; Contingent Negative Variation; Electroencephalography; | 2002 |
Phencyclidine and ketamine intoxication: a study of four populations of recreational users.
Topics: Hallucinations; Humans; Ketamine; Phencyclidine; Psychoses, Substance-Induced; Substance-Related Dis | 1978 |
Phencyclidine: angel dust.
Topics: Adolescent; Adult; Chemical Phenomena; Chemistry; Child; Gastric Lavage; Half-Life; Humans; Illicit | 1979 |
Psychosis and ketamine.
Topics: Anesthetics; Cyclohexanes; Electroconvulsive Therapy; Humans; Ketamine; Psychoses, Substance-Induced | 1972 |
Psychosis and ketamine.
Topics: Adult; Anesthetics; Cyclohexanes; Humans; Ketamine; Preanesthetic Medication; Psychoses, Substance-I | 1972 |
Psychosis and ketamine.
Topics: Adult; Anesthetics; Cyclohexanes; Female; Hallucinations; Humans; Ketamine; Psychoses, Substance-Ind | 1971 |